

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 04-08-2006

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 20-05-2006 TO BE PUBLISHED ON 04-08-2006 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

465/2006	<u>15-5-2006</u> Sanofi Aventis Deutschland GmbH, Germany, (Priority 9-6-05 Germany)	“ Benzooxazol-2- one derivatives as inhibitors of lipases and phospholipases ”
466/2006	Sanofi Aventis Deutschland GmbH, Germany, (Priority 9-6-05 Germany)	“ Azolopyridin –2-one derivatives as inhibitors of lipases and phospholipases ”
467/2006	Honda Motor Co, Ltd, Japan, (Priority 23-6-05 Japan)	“ Engine valve operating system “
468/2006	Glaxo SmithKline Biologicals s.a, Belgium, (Priority 17-5-05 GB)	“ Novel Device”
469/2006	Mr. Eijazuddin, Dr. K. Khan Muhammad Rauf Khan Engr. Muhammad Tariq PCSIR, Peshawar, Pakistan	“A process for the production of garlic paste”
470/2006	<u>16-05-2006</u> Bulher AG, Switzerland (Priority 13-06-05 Germany)	“Grinding machine”
471/2006	Astra Zeneca AB, Sweden, (Priority 23-5-05 Sweden)	“ New compounds I “
472/2006	Astra Zeneca AB, Sweden, (Priority 23-5-05 Sweden)	“ New compounds II“
473/2006	Lojack Operating company LP, USA, (Priority 18-5-05 USA)	“ A vehicle locating unit with improved power management method “

474/2006	Bristol-Myers Squibb Company, USA, (Priority 20-5-05 USA)	“ Pyrrolopyridine – Based inhibitors of dipeptidyl peptidase IV and methods “
475/2006	Centocor Inc, USA, (Priority 19-5-05 USA)	“ Anti - MCP-1 antibodies, compositions, methods and uses “
476/2006	WM International Ltd, Canada, (Priority 17-5-05 USA)	“ Apparatus and method for the non-chemical stablization of bio-solids “
477/2006	Sanofi Aventis Deutschland GmbH, Germany, (Priority 28-6-05 Europe)	“ Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals “
478/2006	Sanofi Aventis Deutschland GmbH, Germany, (Priority 9-6-05 Germany)	“ Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases “
479/2006	National Starch and chemical investment Holding Corporation, USA, (Priority 18-5-05 USA)	“ Flour composition with increased total dietary fiber, process of making, and uses thereof “
480/2006	BASF Aktiengesellschaft, Germany, (Priority 24-5-05 USA)	“ 1-(imidazolin-2-yl) amino-1, 2-diphenylethane compounds for combating animal pests “
481/2006	BASF Aktiengesellschaft, Germany, (Priority 23-5-2005 USA)	“ 1-(1,2-Diphenyl-ethyl)-3-(2-hydroxyethyl)-thiourea compounds for combating animal pests “
482/2006	Zaheer Ali Malik S/o Munawar Ali Malik, Pakistan	“ An improved fuel catalyst device called economax for optimizing combustion and improving engine performance “
<u>17-5-2006</u>		
483/2006	Boehringer Ingelheim International, Germany, (Priority 19-5-05 USA)	“ Derivatives of 6, 7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid “
484/2006	Monsanto Technology LLC, USA (Priority 19-5-05 USA)	“ Post-transcriptional regulation of gene expression “

485/2006	1. Array Biopharma Inc USA 2. AstraZeneca AB, Sweden (Priority 18-5-05 USA)	“ Heterocyclic inhibitors of mek and methods of use thereof “
486/2006	Novartis AG, France (Priority 20-5-05 GB)	“ Imidazoquinolines as lipid kinase inhibitors “
487/2006	Syed Arshad Imran of Syed Ekram Uddin Karachi, Pakistan	“ New unique design and fan base “cool helmet “ for motorcycle and other usages”
	<u>18-5-2006</u>	
488/2006	AstraZeneca AB, Sweden (Priority 27-5-05 GB)	“ Chemical Compounds “
489/2006	AstraZeneca AB, Sweden (Priority 28-5-05 GB)	“ Chemical Compounds “
490/2006	Bayer CropScience AG, Germany (Priority 15-6-05 Japan)	“ Benzanilides with insecticidal activity “
491/2006	Sanofi-Aventis Deutschland GmbH, Germany, (Priority 28-6-05 EP)	“ Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals “
492/2006	Sanofi-Aventis France (Priority 26-5-05 France)	“ Novel 4-[2-oxo-2,3-dihydro-1H-indol-1yl] sul-phonyl] phenylcarbamate derivatives, preparation thereof and therapeutic use thereof “
	<u>19-5-2006</u>	
493/2006	Almirall-prodesfarma, S.A., Spain (Priority 20-5-05 Spain)	“ Derivative of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the B2 adrenergic receptor “
494/2006	Janssen Pharmaceutica N. V. Belgium (Priority 20-5-05 US)	“ Process for preparation of sulfamide derivatives “
495/2006	Vasogen Ireland Limited, Ireland, (Priority 19-5-05 USA)	“ Verification method & system for medical treatment “

496/2006	Vasogen Ireland Limited, Ireland, (Priority 19-5-05 USA)	“ Permission-based material dispenser “
497/2006	Vasogen Ireland Limited, Ireland, (Priority 19-5-05 USA)	“ Sample management unit “
498/2006	BASF Aktiengesellschaft Germany (Priority 30-5-05 Germany)	“ Polymeric composition comprising polyolefins and amphiphilic block copolymers and optionally other polymers and/or fillers and dyes or printing such compositions “
499/2006	<u>20-5-2005</u> 1. Novartis AG, Switzerland 2. Vicuron Pharmaceuticals, Inc USA (Priority 23-5-05 USA)	“ N-formyl hydroxylamine compounds “
500/2006	SmithKline Beecham Corporation, USA (Priority 23-5-05 US)	“ Novel chemical compounds “
501/2006	Au Vitronic Limited, Karachi Pakistan	“ An improved method for manufacturing of composite door panel using injection molding technology “
502/2006	Metecno S.p.A. Italy (Priority 20-5-05 Italy)	“ Transportable apparatus for continuous manufacturing of panels and the like “
503/2006	1. Dr. Shahid Mahmud, 2. Tanzeela Nazir, 3. Razia Khanum and 4. Dr. Amran Waheed PCSIR Laboratories, Lahore	“ A process for the production of anti-acne cream “

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicated their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

631/2004 Unilever Plc,
UK

“A process for shifting lower the level of salt required to produce dilution thickening effect of a composition”

(Class: INT. CL. A61K, 9/08)

139059

This application relates to a process for making single phase dilution thickening composition comprising electrolyte the steps comprising by adding defined associative thickener to said compositions the level of salt/ electrolyte required to obtained dilution thickening effect.

632/2004 Clipsal Australia Pty Ltd.
Australia

“A compact smoke alarm”

(Class: INT.CL. G08B, 5/40)

139060

Comprising; a smoke detection chamber.
A smoke detector mounted to the body for communication within the chamber;
an electrical circuit operatively connected to the smoke detector,
a sound generating device mounted external to the chamber adjacent to the sound inlet aperture, wherein the smoke detection chamber is sized and shaped to cause resonance at the operating frequency of the sound generating device.

636/2004	H. Lundbeck A/S Denmark	<p>“Process for the preparation of succinate and malonate salt of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament“</p> <p>(Class: INT. CL. Co7D, 295/26)</p>	139061
		<p>Comprising to4-((1R, 3S)-6-chloro-3-phenylindan-yl)-1,2,2-trimethylpiperazine compound, to its process of preparation to its pharmaceutical composition containing it useful for the treatment of schizophrenia.</p>	
639/2004	22nd Century Limited, LLC., USA	<p>“Reduced-exposure tobacco products”</p> <p>(Class: INT.CL. A24B, 9/00)</p>	139062
		<p>Comprising an increased-nicotine transgenic plant or plant portion of species of the genus nicotiana wherein such plant portion expresses at least one heterologous nucleic acid that up regulates the production of nicotine in such transgenic plant or plant portion and a tar-to—nicotine yield ratio of between about 3 and about 8 as measured by the FTC or ISO method.</p>	
640//2004	SmithKline Beecham (Cork) Ltd. Eire	<p>“An oral dosage form comprising ropinirole for the treatment of restless legs syndrome”</p> <p>(Class: INT.CL. A61K, 9/20)</p>	139063
		<p>Characterized in that the mean duration taken to achieve the half peak plasma concentration (1/2 Cmax)of ropinirole in-vivo is less than 3 hours after administration of the oral dosage form; and the mean duration above half peak plasma concentration (1/2Cmax) of ropinirole in-vivo is 7 to 13 hours.</p>	
641/2004	Vital Earth Technologies Pty. Ltd., Australia	<p>“Method and apparatus for condensing water from ambient air”</p> <p>(Class: F28B, 9/08)</p>	139064

Comprising providing at least one condensation surface for contact with ambient air, passing a gas into an enclosed space containing a gaseous mixture of the gas and refrigerant vapour evaporated from a liquid refrigerant, passing the gaseous mixture from the enclosed space, contacting the cooled condensation surface with ambient air.

649/2004 Nokia Corporation,
Finland

“A network element for controlling the operation of mobile devices”

(Class: H03K, 7/00)

139065

Characterized in that the network element has means for coding the threshold values which in such a way that one part of the mapping is kept unchanged and another part of the mapping is changed in order to enable the different interpretation of the certain measurable parameter.

661/2004 Novartis AG,
Switzerland

“A process for the purification of terbinafine”

(Class: INT.CL. C07C, 13/48)

139066

Comprising to (E)-N-(6, 6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine compound, in free base form to distillation and recovering the resultant product in free base or acid addition salt form.

415/2006 H. Lundbeck A/S,
Denmark

“Succinate and malonate salt of trans-4-(1R, 3S)-6-chloro-3-phenylindan-1-YL)-1, 2, 2-trimethylpiperazine and the use as a medicament”

(Class: INT.CL. C07D, 295/26)

139067

Comprising to 4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1, 2, 2-trimethylpiperazine compound, to its pharmaceutical composition containing it, useful for the treatment of schizophrenia.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-8 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

138907	Sanofi-Aventis Deutschland GmbH, Germany	281/2004
138908	Avanir Pharmaceuticals, USA	288/2004
138909	HF Arzneimittelforschung GmbH Germany	294/2004
138910	Imperial Chemical Industries Plc. UK	583/2004
138911	Saima Latif, Fahmida Perveen, Khaula Shirin, PCSIR, Karachi.	906/2004
138912	Avanir Pharmaceuticals, USA	44/2006

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488